Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05024929 · ClinicalTrials.gov registry record
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
A clinical trial of Pediatric Cancer and Papillary Thyroid Cancer, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- 32
- Enrollment target
- 9
- Study locations
NCT05024929 is a study of Pediatric Cancer and Papillary Thyroid Cancer that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 32 participants, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (98% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT05024929, a study of Pediatric Cancer and Papillary Thyroid Cancer, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- 32 participants
- Enrollment target
- 9
- Study locations
Study Summary
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.
Conditions Studied
Interventions
- PROCEDURE Whole body scan
Study Locations (9)
Texas
- MD Anderson Cancer Center - Houston
- Texas Children's Hospital - Houston
California
- University of California San Francisco - San Francisco
Georgia
- Emory University School of Medicine - Atlanta
Massachusetts
- Boston Children's Hospital - Boston
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- St. Jude Children's Research Hospital - Memphis
Washington
- Seattle Children's Hospital - Seattle
New South Wales
- Children's Hospital Westmead - Sydney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2033-02-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05024929
The ClinicalTrials.gov registry entry for NCT05024929 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Whole body scan is the first listed.
NCT05024929 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05024929 about?
NCT05024929 is a clinical study titled "Targeted Therapy to Increase RAI Uptake in Metastatic DTC". Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drug...
What is the current status of trial NCT05024929?
This trial is currently recruiting. The enrollment target is 32 participants. The study started on 2021-07-16. Estimated completion is 2033-02-01.
What conditions does trial NCT05024929 study?
This clinical trial studies the following conditions: Pediatric Cancer, Papillary Thyroid Cancer, Differentiated Thyroid Cancer.
What interventions are being tested in trial NCT05024929?
The interventions under investigation include: Whole body scan (PROCEDURE).
Who is sponsoring clinical trial NCT05024929?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05024929 being conducted?
This trial has 9 study locations across California, Georgia, Massachusetts, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LIFE Cancer Survivorship Database for Pediatric Cancer
RECRUITING
-
Multisite Implementation of COMPRENDO
RECRUITING · NA
-
Childhood Cancer Predisposition Study (CCPS)
RECRUITING
-
Ovarian Tissue Cryopreservation in Post Pubertal (OTC-Post Pubertal)
RECRUITING
-
Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer
RECRUITING · NA
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.